参考文献/References:
[1]Torre LA,Bray F,Siegel RL,et al.Global cancer statistics,2012.CA Cancer J Clin,2015,65(2):87-108.
[2]Stukan M,Alcazar JL,Gbicki J,et al.Ultrasound and clinical preoperative characteristics for discrimination between ovarian metastatic colorectal cancer and primary ovarian cancer:a casecontrol study.Diagnostics (Basel),2019,9(4):210.
[3]Coleman MP,Quaresma M,Berrino F,et al.Cancer survival in five continents:a worldwide populationbased study (CONCORD).Lancet Oncol,2008,9(8):730-756.
[4]Sung JJ,Lau JY,Goh KL,et al.Increasing incidence of colorectal cancer in Asia:implications for screening.Lancet Oncol,2005,6(11):871-876.
[5]Bridgewater JA,Pugh SA,Maishman T,et al.Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC):longterm results of a multicentre,randomised,controlled,phase 3 trial.Lancet Oncol,2020,21(3):398-411.
[6]McCormick CC,Giuntoli RL 2nd,Gardner GJ,et al.The role of cytoreductive surgery for colon cancer metastatic to the ovary.Gynecol Oncol,2007,105(3):791-795.
[7]Ganesh K,Shah RH,Vakiani E,et al.Clinical and genetic determinants of ovarian metastases from colorectal cancer.Cancer,2017,123(7):1134-1143.
[8]Zhou R,Liu Y,Wang Y,et al.Clinicopathological characteristics and prognosis analysis of ovarian metastases in colorectal cancer:a singlecenter experience. Int J Clin Oncol,2020,25(10):1822-1829.
[9]Kurokawa R,Nakai Y,Gonoi W,et al.Differentiation between ovarian metastasis from colorectal carcinoma and primary ovarian carcinoma:evaluation of tumour markers and “millefeuille sign” on computed tomography/magnetic resonance imaging.Eur J Radiol,2020,124:108823.
[10]Kubeek O,Laco J,paek J,et al.The pathogenesis,diagnosis,and management of metastatic tumors to the ovary:a comprehensive review.Clin Exp Metastasis,2017,34(5):295-307.
[11]Kim DD,Park IJ,Kim HC,et al.Ovarian metastases from colorectal cancer:a clinicopathological analysis of 103 patients.Colorectal Dis,2009,11(1):32-38.
[12]Omranipour R,Abasahl A.Ovarian metastases in colorectal cancer.Int J Gynecol Cancer,2009,19(9):1524-1528.
[13]Fujiwara A,Noura S,Ohue M,et al.Significance of the resection of ovarian metastasis from colorectal cancers.J Surg Oncol,2010,102(6):582-587.
[14]Chung TS,Chang HJ,Jung KH,et al.Role of surgery in the treatment of ovarian metastases from colorectal cancer.J Surg Oncol,2009,100(7):570-574.
[15]黄深,张森,高枫,等.380例结直肠癌卵巢转移的相关因素分析.中国肿瘤临床,2011,38(2):89-93.
[16]Kato MK,Shida D,Yoneoka Y,et al.Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance.Int J Clin Oncol,2020,25(9):1663-1671.
[17]Choi HJ,Lee JH,Kang S,et al.Contrastenhanced CT for differentiation of ovarian metastasis from gastrointestinal tract cancer: stomach cancer versus colon cancer.AJR Am J Roentgenol,2006,187(3):741-745.
[18]宋望,郑洪涂,徐烨.结肠直肠癌卵巢转移的研究进展.外科理论与实践,2017,22(3):261-264.
[19]Kanellos I,Demetriades H,Zintzaras E,et al.Incidence and prognostic value of positive peritoneal cytology in colorectal cancer.Dis Colon Rectum,2003,46(4):535-539.
[20]Ursem C,Zhou M,Paciorek A,et al.Clinicopathologic characteristics and impact of oophorectomy for ovarian metastases from colorectal cancer.Oncologist,2020,25(7):564-571.
[21]Jiang R,Tang J,Cheng X,et al.Surgical treatment for patients with different origins of Krukenberg tumors: outcomes and prognostic factors.Eur J Surg Oncol,2009,35(1):92-97.
[22]Bakkers C,van der Meer R,Roumen RM,et al.Incidence,risk factors,treatment,and survival of ovarian metastases of colorectal origin:a Dutch populationbased study.Int J Colorectal Dis,2020,35(6):1035-1044.
[23]AlBusaidi IS,Bailey T,Dobbs B,et al.Complete resection of colorectal cancer with ovarian metastases combined with chemotherapy is associated with improved survival.ANZ J Surg,2019,89(9):1091-1096.
[24]Bruchim I,BenHarim Z,Piura E,et al.Preoperative clinical and radiological features of metastatic ovarian tumors.Arch Gynecol Obstet,2013,288(3):615-619.
[25]Kikkawa F,Shibata K,Ino K,et al.Preoperative findings in nongynecologic carcinomas metastasizing to the ovaries.Gynecol Obstet Invest,2002,54(4):221-227.
[26]Guzel AB,Gulec UK,Paydas S,et al.Preoperative evaluation,clinical characteristics,and prognostic factors of nongenital metastatic ovarian tumors:review of 48 patients.Eur J Gynaecol Oncol,2012,33(5):493-497.
[27]Kammar PS,Engineer R,Patil PS,et al.Ovarian metastases of colorectal origin: treatment patterns and factors affecting outcomes.Indian J Surg Oncol,2017,8(4):519-526.
[28]Lionetti R,De Luca M,Travaglino A,et al.Treatments and overall survival in patients with Krukenberg tumor.Arch Gynecol Obstet,2019,300(1):15-23.
[29]Erroi F,Scarpa M,Angriman I,et al.Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy.J Surg Oncol,2007,96(2):113-117.
[30]Ayhan A,Guvenal T,Salman MC,et al.The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.Gynecol Oncol,2005,98(2):235-241.
[31]Kim WY,Kim TJ,Kim SE,et al.The role of cytoreductive surgery for nongenital tract metastatic tumors to the ovaries.Eur J Obstet Gynecol Reprod Biol,2010,149(1):97-101.
[32]Laughlin GA,BarrettConnor E,KritzSilverstein D,et al.Hysterectomy,oophorectomy,and endogenous sex hormone levels in older women:the Rancho Bernardo Study.J Clin Endocrinol Metab,2000,85(2):645-651.
[33]Chang GJ,Kaiser AM,Mills S,et al.Practice parameters for the management of colon cancer.Dis Colon Rectum,2012,55(8):831-843.
[34]Evers DJ,Verwaal VJ.Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin.Br J Surg,2011,98(2):287-292.
[35]Goéré D,Daveau C,Elias D,et al.The differential response to chemotherapy of ovarian metastases from colorectal carcinoma.Eur J Surg Oncol,2008,34(12):1335-1339.
[36]Sekine K,Hamaguchi T,Shoji H,et al.Retrospective analyses of systemic chemotherapy and cytoreductive surgery for patients with ovarian metastases from colorectal cancer:a singlecenter experience.Oncology,2018,95(4):220-228.
[37]Quenet F,Elias D,Roca L,et al.A UNICANCER phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC):PRODIGE 7.J Clin Oncol,2018,36(18 Suppl):LBA3503.